We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
+9.3%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$282M
AUM Growth
+$52.2M
Cap. Flow
+$37.1M
Cap. Flow %
13.15%
Top 10 Hldgs %
53.18%
Holding
123
New
20
Increased
19
Reduced
30
Closed
30

Top Buys

Rank Stock Value
1
GDX icon
VanEck Gold Miners ETF
GDX
+$2.1M
2
ALT icon
Altimmune
ALT
+$1.99M
3
PFE icon
Pfizer
PFE
+$1.94M
4
PSFE icon
Paysafe
PSFE
+$1.38M
5
F icon
Ford
F
+$1.2M

Top Sells

Rank Stock Value
1
ORCL icon
Oracle
ORCL
+$3.33M
2
ABBV icon
AbbVie
ABBV
+$2.82M
3
T icon
AT&T
T
+$1.96M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$1.83M
5
GLD icon
SPDR Gold Trust
GLD
+$1.7M

Sector Composition

Rank Sector Weight
1 Healthcare 28.83%
2 Technology 11.75%
3 Communication Services 8.8%
4 Financials 4.55%
5 Consumer Discretionary 3.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QTNT
76
DELISTED
Quotient Limited Ordinary Shares
QTNT
$368K 0.13%
2,525
-763
-23% -$122K
APTV icon
77
Aptiv
APTV
$12B
$354K 0.13%
2,250
-5,250
-70% -$769K
BIIB icon
78
Biogen
BIIB
$30B
$346K 0.12%
+1,000
New +$303K
ARNA
79
DELISTED
Arena Pharmaceuticals Inc
ARNA
$341K 0.12%
5,000
– –
LIT icon
80
CALL
Global X Lithium & Battery Tech ETF
LIT
$1.51B
$326K 0.12%
+4,500
New +$290K
APTX
81
DELISTED
Aptinyx Inc. Common Stock
APTX
$323K 0.11%
114,000
-16,000
-12% -$44.7K
TSM icon
82
TSMC
TSM
$2.1T
$300K 0.11%
+2,500
New +$293K
MTNB icon
83
Matinas BioPharma
MTNB
$1.88M
$299K 0.11%
7,719
-281
-4% -$12.1K
MAS icon
84
CALL
Masco
MAS
$14.1B
$295K 0.1%
+5,000
New +$308K
TBHC
85
DELISTED
The Brand House Collective
TBHC
$252K 0.09%
11,000
+500
+5% +$13.4K
XLE icon
86
PUT
State Street Energy Select Sector SPDR ETF
XLE
$39.6B
$242K 0.09%
+9,000
New +$234K
PARA
87
CALL
DELISTED
Paramount Global Class B
PARA
$226K 0.08%
+5,000
New +$206K
AIRT icon
88
Air T
AIRT
$75.5M
$214K 0.08%
+8,673
New +$199K
LCTX icon
89
Lineage Cell Therapeutics
LCTX
$269M
$212K 0.08%
74,500
+53,500
+255% +$138K
MU icon
90
CALL
Micron Technology
MU
$930B
$212K 0.08%
2,500
-10,000
-80% -$844K
SGMO
91
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$157K 0.06%
13,100
-900
-6% -$10.2K
OBSV
92
DELISTED
ObsEva SA Ordinary Shares
OBSV
$80K 0.03%
26,500
– –
SPFR.WS
93
DELISTED
Jaws Spitfire Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one Cl
SPFR.WS
$58K 0.02%
+30,000
New +$52.4K
ABBV icon
94
CALL
AbbVie
ABBV
$443B
– –
-7,500
Closed -$812K
ADT icon
95
ADT
ADT
$5.58B
– –
-14,000
Closed -$118K
AMD icon
96
CALL
Advanced Micro Devices
AMD
$776B
– –
-7,500
Closed -$589K
BDX icon
97
CALL
Becton Dickinson
BDX
$45.6B
– –
-2,563
Closed -$608K
BOX icon
98
CALL
Box
BOX
$4.37B
– –
-12,500
Closed -$287K
CRM icon
99
Salesforce
CRM
$151B
– –
-1,250
Closed -$265K
CVS icon
100
CVS Health
CVS
$133B
– –
-21,500
Closed -$1.62M
1 2 3
4
5

Similar funds

JIC
JRM Investment Counsel Omaha, Nebraska $375M AUM 13.43% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
AIM
Access Investment Management Atlanta, Georgia $376M AUM 17.2% 1-Year Est. Return
MWM
McMill Wealth Management Norfolk, Nebraska $376M AUM 14.46% 1-Year Est. Return
RCP
RIT Capital Partners London, United Kingdom $374M AUM 25.18% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
CAG
Compass Advisory Group Melville, New York $374M AUM 14.59% 1-Year Est. Return
LWMNY
Landmark Wealth Management (New York) Melville, New York $373M AUM 12.01% 1-Year Est. Return

DCF Advisers's Q2 2021 Portfolio in Review

As of Q2 2021, DCF Advisers held 123 positions worth $282M, up 23% from $230M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

DCF Advisers deployed $37.1M of net new capital in Q2 2021, opening 20 new positions and adding to 19 existing holdings. Its largest new stake was Altimmune: 145,750 shares worth $1.44M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 35% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Oracle, an estimated $3.33M trimmed.

  • DCF Advisers's largest Q2 2021 buy was Altimmune: 145,750 shares worth $1.44M.
  • DCF Advisers added most to VanEck Gold Miners ETF in Q2 2021, an estimated $2.1M increase.
  • DCF Advisers's biggest Q2 2021 reduction was Oracle, cutting an estimated $3.33M.
  • DCF Advisers fully exited CVS Health in Q2 2021, selling an estimated $1.62M.
  • DCF Advisers's ten largest holdings make up 53% of its $282M portfolio in Q2 2021.
  • DCF Advisers opened 20 new positions and closed 30 in Q2 2021.
  • DCF Advisers's portfolio value rose 23% quarter-over-quarter to $282M.

Based on DCF Advisers's 13F filing for Q2 2021, filed 13 Aug 2021.